Abstract:Type 2A/IIC von Willebrand Disease (VWD) is caused by mutations in the propeptide of von Willebrand Factor (VWF), and characterized by the impaired multimer assembly. The structural analysis revealed that VWF propeptide (D1D2 domain) serves as a pH-sensing template for VWF multimerization and tubular storage, which implies that D1D2 expression "in trans" has the potential to restore the multimerization defect of type 2A/IIC mutatns. The gene therapy of VWD is challenging due to the huge size of VWF gene, which cannot be packed to the virus vectors, particularly recombinant adeno-associated virus (rAAV). In the pilot studies, we had co-transfected AtT20 cell with plasmid encoding full length VWF, containing the Y87S mutation on propeptide region and causing type 2A VWD phenotype, and plasmid expressing only wild type propeptide of VWF. The co-transfection rescued the multimer formation in a concentration dependent manner (Figure 1A )and corrected the functional defects caused by the Y87S mutation (Figure 1B). Inspired by the results of in vitro studies, we thus have designed a novel gene therapy strategy for type 2A VWD utilizing the machinery of VWF multimer assembling. Instead of trying to squeeze the VWF gene into the AAV vector, we had prepared the AAV vector containing the expression cassette of propeptide region directed by endothelial cell specific promoter FLT-1. The mouse model representing natural occurring VWF Y87S mutation identified in type 2A VWD patient was established by criper9 gene editing technique. The AAV vectors was administered via tail vein injection at a dose of 5Ⅹ1011 genome copies to 6 weeks old male mice to deliver the propeptide of VWF gene and the plasma of the treated mice was collected retroorbital pretreatment and at 2- ,4- and 6-weeks post vector injection. The antigen level of VWF was determined by ELISA and the function activity of VWF was measured by collagen binding assay. The status of VWF multimerization was examined by agarose gel electrophoresis. Although the Y87S mutation led to significant reduce of high molecule weight multimer in mice, unlike observed in mutation harboring patient, the mice still had medium and low molecular weight multimer, maintaining ~30% of activity. The expression of propeptide by AAV delivered vector improved the VWF activity significantly to ~70% of wild type control (Figure 1C), and restored the formation of high molecular weight multimer (Figure 1D). The experimental gene therapy conducted on VWD mouse model showed that it would be efficient to express the propeptide alone to correct the type 2A/IIC VWD defect and the preliminary results provide a novel strategy to overcome technique limits on gene therapy of VWD. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options

A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD

The Experimental Gene Therapy on Type 2a/iic VWD Mouse Model with AAV Vector Delivering Only VWF Propeptide Expression Cassette4

A Humanized Glycoprotein Vi (Gpvi) Mouse Model To Assess The Antithrombotic Efficacies Of Anti-Gpvi Agents

von Willebrand disease: what does the future hold?

Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice

Progress in von Willebrand Disease Treatment: Evolution towards Newer Therapies

A New Mouse Model for Wound Healing in Hemophilia A.

Intraosseous Delivery of Platelet-Targeted Factor VIII Lentiviral Vector in Humanized NBSGW Mice

A novel inducible von Willebrand Factor Cre Recombinase mouse strain to study microvascular endothelial cell-specific biological processes

A novel inducible von Willebrand Factor Cre recombinase mouse strain to study microvascular endothelial cell-specific biological processes in vivo

Diagnosis and treatment of von Willebrand disease in 2024 and beyond

In Vitro and in Vivo Model Systems for Hemophilia A Gene Therapy.

Visualizing the Von Willebrand Factor/glycoprotein Ib-IX Axis with a Platelet-Type Von Willebrand Disease Mutation.

A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency

Plasmin-cleaved Von Willebrand Factor as a biomarker for microvascular thrombosis

Abstract 125: Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant

Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene

Abstract 12567: A Novel Mouse Model Replicates Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia

Generation of humanized mouse models to support therapeutic development for SYNGAP1 and STXBP1 disorders